Gene Silencing: A Therapeutic Approach to Combat Influenza Virus Infections

Khanna, Madhu; Saxena, Latika; Rajput, Roopali; Kumar, Binod; Prasad, Rajendra

doi:10.2217/fmb.14.94

Cited by 18 publications

(9 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RNA inhibitors are able to regulate the expression of influenza viral RNAs. Accordingly, viral genes became a potential target and RNA inhibitors may be effective in influenza treatment (300).…”

Section: Other Targets and Strategiesmentioning

confidence: 99%

Progress of small molecular inhibitors in the development of anti-influenza virus agents

Wu¹,

Wu²,

Sun³

et al. 2017

Theranostics

View full text Add to dashboard Cite

The influenza pandemic is a major threat to human health, and highly aggressive strains such as H1N1, H5N1 and H7N9 have emphasized the need for therapeutic strategies to combat these pathogens. Influenza anti-viral agents, especially active small molecular inhibitors play important roles in controlling pandemics while vaccines are developed. Currently, only a few drugs, which function as influenza neuraminidase (NA) inhibitors and M2 ion channel protein inhibitors, are approved in clinical. However, the acquired resistance against current anti-influenza drugs and the emerging mutations of influenza virus itself remain the major challenging unmet medical needs for influenza treatment. It is highly desirable to identify novel anti-influenza agents. This paper reviews the progress of small molecular inhibitors act as antiviral agents, which include hemagglutinin (HA) inhibitors, RNA-dependent RNA polymerase (RdRp) inhibitors, NA inhibitors and M2 ion channel protein inhibitors etc. Moreover, we also summarize new, recently reported potential targets and discuss strategies for the development of new anti-influenza virus drugs.

show abstract

Section: Other Targets and Strategiesmentioning

confidence: 99%

Progress of small molecular inhibitors in the development of anti-influenza virus agents

Wu¹,

Wu²,

Sun³

et al. 2017

Theranostics

View full text Add to dashboard Cite

show abstract

“…In this application, several siRNAs targeting conserved regions of the influenza virus genome have been combined to form a cocktail that has a multitargeted approach. 88 Furthermore, Rajput et al reported that when NS1-specific siRNA was administered in experimental mice, a 92% reduction was observed in the levels of NS1 gene expression in the lungs. 98 Significant decrease in cytokine levels and virus titers in the lungs were also observed.…”

Section: Possibility Of Use As Anti-influenza Agent In Human and Animalsmentioning

confidence: 99%

Treatment of Influenza: Prospects of Post-Transcriptional Gene Silencing Through Synthetic siRNAs

Adeola¹

2017

Exploratory Research and Hypothesis in Medicine

View full text Add to dashboard Cite

Influenza continues to pose significant threats to global health. The disease remains life-threatening, especially in children, the elderly and immunocompromised patients. High mutation rate and genetic reassortment enhance antigenic diversity and generation of novel strains. These, and other related factors, have made influenza viruses more resistant to control strategies and have necessitated the need for development of novel and effective strategies for prevention and treatment of influenza. While vaccination is the preferred method for prevention of influenza virus infections, preparation of influenza vaccines has to be carried out annually, and this takes several months. Anti-influenza drugs would, therefore, be the most immediate resource for combating newly emerging influenza viruses, especially if available vaccines proved ineffective. This review discusses the prospects of using small interfering RNAs (siRNAs) for treatment of influenza. Challenges associated with anti-influenza RNA interference (RNAi) and future directions are also highlighted

show abstract

“…Despite progress made in the 20 th century with the introduction of antibiotics, vaccines and antivirals, there are no specific interventions for most respiratory infections of viral origin. Although, the recent years have witnessed a tremendous development in the management of respiratory viruses including influenza and other respiratory viral infections, the world still suffers from these viral infections every year leading to an increase in morbidity and mortality [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Respiratory Virus Pathogen from Patients Presenting with Influenza like Illness at Various Hospitals in Delhi, India

Khanna¹

2019

PMRR

Self Cite

View full text Add to dashboard Cite

Background: Respiratory viruses have been widely circulating in human populations and its variants have caused, and continue to cause, substantial morbidity and mortality worldwide. Objective:The objective of this study was to compare the presence of various circulating respiratory virus among the population in Delhi region. Materials and Method: The epidemiology and burden of human respiratory viruses were examined in a cohort of 106 patients from Delhi, India, by using real-time quantitative reverse transcription polymerase chain reaction. Results: Of the 106 screened samples tested,35.84% patients were found positive for influenza A virus, 19.81% for Human Metapneumovirus (hMPV),5.66% for Rhinovirus (HRV), 3.77%for Parainfluenza (PIV) type 4 and Human Enterovirus (HEV), 2.83% for Human Coronavirus (HCoV) OC43, while 0.94% for influenza B, coronavirus NL63 and 229E, Parainfluenza type-2 and 3 and Bocavirus. The analysis revealed that Parainfluenza (PIV-1, 2 and 3), Respiratory Syncytial Virus (RSV) A and B, and Human Bocavirus (HBoV) are not commonly circulating among general population. Conclusion: The metapneumovirus and influenza A virus are important respiratory pathogens in patients. Apart from these HRV and HEV embark to the clinical significance in child care. Influenza and HRV caused the highest-impact illnesses. The current study depicts the burden of respiratory viruses in current population.

show abstract

Gene Silencing: A Therapeutic Approach to Combat Influenza Virus Infections

Cited by 18 publications

References 74 publications

Progress of small molecular inhibitors in the development of anti-influenza virus agents

Progress of small molecular inhibitors in the development of anti-influenza virus agents

Treatment of Influenza: Prospects of Post-Transcriptional Gene Silencing Through Synthetic siRNAs

Evaluation of Respiratory Virus Pathogen from Patients Presenting with Influenza like Illness at Various Hospitals in Delhi, India

Contact Info

Product

Resources

About